NCT01979016 - Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

January 31, 2015

Conditions

Atopic Dermatitis (AD)

Interventions

DRUG

Dupilumab

DRUG

Placebo

Matching placebo

OTHER

Background treatment

Participants were required to apply stable doses of a topical emollient (moisturizer) twice daily for at least 7 days before the baseline visit and at least 7 days after the baseline visit (day -7 to day 8).

Trial Locations (4)

Unknown

Chicago

New York

Dallas

Montreal